Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Equities researchers at HC Wainwright dropped their Q3 2025 earnings estimates for Aura Biosciences in a research note issued on Wednesday, August 13th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($0.47) for the quarter, down from their prior forecast of ($0.46). HC Wainwright currently has a "Buy" rating and a $22.00 price target on the stock. The consensus estimate for Aura Biosciences' current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Aura Biosciences' Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.99) EPS, FY2026 earnings at ($2.15) EPS, FY2027 earnings at ($1.97) EPS, FY2028 earnings at ($1.70) EPS and FY2029 earnings at ($1.32) EPS.
Separately, JMP Securities reaffirmed a "market outperform" rating and set a $19.00 price target on shares of Aura Biosciences in a research report on Friday, May 23rd. Two investment analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. Based on data from MarketBeat.com, Aura Biosciences presently has an average rating of "Buy" and a consensus target price of $22.00.
Get Our Latest Research Report on AURA
Aura Biosciences Stock Down 4.3%
Shares of AURA stock traded down $0.29 on Friday, hitting $6.40. 105,330 shares of the stock were exchanged, compared to its average volume of 157,672. Aura Biosciences has a fifty-two week low of $4.34 and a fifty-two week high of $12.38. The business has a 50-day moving average of $6.62 and a 200 day moving average of $6.50.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its earnings results on Wednesday, August 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02.
Insiders Place Their Bets
In other Aura Biosciences news, SVP Amy Elazzouzi sold 7,722 shares of the firm's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $6.70, for a total transaction of $51,737.40. Following the completion of the sale, the senior vice president owned 86,558 shares of the company's stock, valued at $579,938.60. This trade represents a 8.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 6.30% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of AURA. Tower Research Capital LLC TRC grew its position in shares of Aura Biosciences by 49.3% in the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company's stock valued at $40,000 after purchasing an additional 2,104 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new position in Aura Biosciences in the 2nd quarter valued at $31,926,000. Gallagher Fiduciary Advisors LLC acquired a new position in Aura Biosciences in the 2nd quarter valued at $189,000. BNP Paribas Financial Markets increased its position in Aura Biosciences by 286.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,499 shares of the company's stock worth $85,000 after buying an additional 10,007 shares during the period. Finally, Bridgeway Capital Management LLC acquired a new stake in shares of Aura Biosciences during the second quarter worth $102,000. Institutional investors and hedge funds own 96.75% of the company's stock.
About Aura Biosciences
(
Get Free Report)
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Further Reading
Before you consider Aura Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.
While Aura Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access